Arkadios Wealth Advisors Buys 2,354 Shares of Icon Plc $ICLR

Arkadios Wealth Advisors boosted its stake in Icon Plc (NASDAQ:ICLR) by 30.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,182 shares of the medical research company’s stock after acquiring an additional 2,354 shares during the period. Arkadios Wealth Advisors’ holdings in Icon were worth $1,481,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. SVB Wealth LLC purchased a new stake in shares of Icon during the 1st quarter worth approximately $28,000. Ameritas Advisory Services LLC bought a new position in Icon during the second quarter valued at $48,000. LRI Investments LLC purchased a new position in shares of Icon during the 2nd quarter valued at $49,000. Blue Trust Inc. lifted its position in shares of Icon by 44.0% during the 2nd quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock valued at $57,000 after buying an additional 120 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its position in shares of Icon by 40,800.0% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 409 shares of the medical research company’s stock valued at $59,000 after buying an additional 408 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Cowen restated a “hold” rating on shares of Icon in a research note on Friday, October 24th. Robert W. Baird set a $220.00 price objective on shares of Icon in a report on Friday, October 24th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Icon in a report on Wednesday, October 8th. Leerink Partners set a $220.00 target price on Icon in a research report on Thursday, October 23rd. Finally, Rothschild & Co Redburn upgraded Icon from a “neutral” rating to a “buy” rating and increased their target price for the stock from $184.00 to $236.00 in a research report on Wednesday, September 3rd. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $207.14.

Icon Stock Performance

NASDAQ ICLR opened at $171.82 on Friday. The stock has a market capitalization of $13.88 billion, a PE ratio of 23.25, a P/E/G ratio of 3.04 and a beta of 1.23. Icon Plc has a 1 year low of $125.10 and a 1 year high of $231.89. The company’s 50 day simple moving average is $178.16 and its two-hundred day simple moving average is $159.38. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $3.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.28 by $0.03. The firm had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $1.98 billion. Icon had a return on equity of 10.58% and a net margin of 7.40%.The company’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter last year, the company posted $3.35 EPS. Analysts predict that Icon Plc will post 13.38 earnings per share for the current fiscal year.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.